AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug
AstraZeneca is betting that Ionis' second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn't.
Ionis developed Tegsedi for years...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.